62484-29-1

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
2,4,8-Trichloroquinazoline is utilized as a key intermediate in the synthesis of certain pharmaceuticals and agrochemicals, contributing to the development of new drugs and pesticides. Its chemical properties allow for the creation of a variety of compounds with specific therapeutic or pesticidal effects.
Used in Dye Manufacturing:
In the dye industry, 2,4,8-trichloroquinazoline is employed as a building block for the production of various dyes. Its unique molecular structure enables the creation of dyes with distinct color characteristics and properties, suitable for different applications.
Used in Polymer Production:
2,4,8-trichloroquinazoline also plays a role in the manufacturing of polymers, where it can be incorporated into the polymer backbone or used as a monomer to create polymers with specific properties. This contributes to the development of new materials with tailored characteristics for various industrial uses.
Used in Industrial Product Manufacturing:
Beyond the aforementioned applications, 2,4,8-trichloroquinazoline is involved in the production of other industrial products, highlighting its versatility and importance in multiple sectors.
Used in Medical Research:
Due to its potential biological activity, 2,4,8-trichloroquinazoline is being studied for possible applications in medical research. Its exploration may lead to the discovery of new therapeutic agents or contribute to a better understanding of biological processes.

InChI:InChI=1/C8H3Cl3N2/c9-5-3-1-2-4-6(5)12-8(11)13-7(4)10/h1-3H

Upstream product

• 32315-10-9 bis(trichloromethyl) carbonate 
• 53312-77-9 2-amino-3-chlorobenzonitrile 
• 74396-74-0 7-Chloroindole-2,3-dione 3-Oxime 
• 62484-22-4 8-chloroquinazoline-2,4-diol 
• 6388-47-2 2-amino-3-chlorobenzoic acid 
• 62484-22-4 8-chloro-2,4-dioxo-1,2,3,4-tetrahydroquinazoline 

Downstream Products

• 62484-39-3 2,8-dichloroquinazolin-4(3H)-one 
• 1107694-84-7 2,8-dichloroquinazoline-4-amine 
• 1616708-00-9 N’-(8-chloro-2-(2,4-dimethoxybenzylamino)quinazolin-4-yl)-3,3-dimethoxypropanehydrazide 
• 1616708-01-0 7-chloro-N-(2,4-dimethoxybenzyl)-2-(2,2-dimethoxyethyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine 
• 1616707-97-1 2-(7-chloro-5-(2,4-dimethoxybenzylamino)-[1,2,4]triazolo[1,5-c]quinazolin-2-yl)acetaldehyde 
• 1664398-52-0 7-chloro-5-(2,4-dimethoxyphenyl)-2-(2-(5-fluoroisoindolin-2-yl)ethyl)[1,2,4]triazolo[1,5-c]quinazoline 
• 19407-55-7 8-Chloro-2-phenylquinazolin-4(3H)-one 
• 769158-11-4 2-((2,8-dichloro-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile 

Relevant academic research and scientific papers

One-pot cascade ring enlargement of isatin-3-oximes to 2,4-dichloroquinazolines mediated by bis(trichloromethyl)carbonate and triarylphosphine oxide

An efficient and convenient one-pot cascade synthesis of 2,4-dichloroquinazolines directly from isatin-3-oximes with the addition of bis(trichloromethyl)carbonate and triarylphosphine oxide was developed, leading to substituted quinazolines in moderate to excellent yields. The efficiency of this transformation was demonstrated by compatibility with a range of functional groups. Thus, the method represents a convenient and practical strategy for the synthesis of substituted 2,4-dichloroquinazolines.

Application of quinazoline and pyrido[3,2-: D] pyrimidine templates to design multi-targeting agents in Alzheimer's disease

A quinazoline and pyrido[3,2-d]pyrimidine based compound library was designed, synthesized and evaluated as multi-targeting agents aimed at Alzheimer's disease (AD). The SAR studies identified compound 8h (8-chloro-N2-isopropyl-N4-ph

HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS

The invention relates to heterocyclic compounds and their use as antibiotics and/or as antibiotic potentiators. The compounds may act as colistin potentiators and SOS inhibitors.

HETEROBICYCLO-SUBSTITUTED-7-METHOXY-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES

Disclosed are compounds of Formulae A defined herein, which have specific binding on an A2A-receptor and are useful for quantifying in vivo receptor-site occupancy of various compounds which have an affinity for binding to an A2A receptor.

HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES

Disclosed are compounds of Formula Gl (structurally represented): where "RG3" "Rd1" to "Rd4", "n", "m", "p", "W", "X", "Y", and "Z" are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDER

Disclosed are compounds of heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine herein, which have specific binding on an A2A-receptor and are useful for quantifying in vivo receptor-site occupancy of various compounds which have an affinity for binding to an A2A-receptor.

Antileishmanial activity of a series of N2, N 4-disubstituted quinazoline-2,4-diamines

A series of N2,N4-disubstituted quinazoline-2,4- diamines has been synthesized and tested against Leishmania donovani and L. amazonensis intracellular amastigotes. A structure-activity and structure-property relationship study was conducted in part using the Topliss operational scheme to identify new lead compounds. This study led to the identification of quinazolines with EC50 values in the single digit micromolar or high nanomolar range in addition to favorable physicochemical properties. Quinazoline 23 also displayed efficacy in a murine model of visceral leishmaniasis, reducing liver parasitemia by 37% when given by the intraperitoneal route at 15 mg kg-1 day-1 for 5 consecutive days. Their antileishmanial efficacy, ease of synthesis, and favorable physicochemical properties make the N2,N 4-disubstituted quinazoline-2,4-diamine compound series a suitable platform for future development of antileishmanial agents.

Facile and efficient cyclization of anthranilonitrile to 2,4-dichloroquinazoline by bis(trichloromethyl) carbonate and catalytic amount triphenylphosphine oxide

2,4-Dichloroquinazolines were synthesized by the cyclization of anthranilonitrile using bis(trichloromethyl) carbonate (BTC) with the aid of catalytic amount of triphenylphosphine oxide (Ph3PO) at 120 °C. This method was also applied to the syn

2-AMINOQUINAZOLINE DERIVATIVE

An object of the present invention is to provide compounds which are useful as protein kinase inhibitors. Disclosed is a 2-aminoquinazoline derivative represented by the following formula (I): wherein R1 represents a lower alkyl group which may be substituted with a halogen atom, or a halogen atom; R2 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a halogen atom, a hydroxyl group, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted acylamino group, a carboxyl group, a lower alkoxycarbonyl group, a carbamoyl group, or a substituted or unsubstituted lower alkylureido group; and X, Y and Z each independently represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a halogen atom, a hydroxyl group, a carboxyl group, a lower alkoxycarbonyl group, a cyano group, a carbamoyl group, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted lower alkoxycarbonylamino group, a substituted or unsubstituted lower alkylaminocarbonyl group, a lower alkylsulfonylamino group, a substituted or unsubstituted lower alkylureido group, or a substituted or unsubstituted acylamino group, or X and Y may be combined to form a 5- to 6-membered ring forming a bicyclic fused ring, wherein the 5- to 6-membered ring may optionally have a substituent, provided that when X and Y are not combined to form a fused ring, R2 represents a hydrogen atom and, when X and Y are combined to form a fused ring, a saturated or unsaturated, bicyclic alicyclic or heterocyclic fused ring can be formed.

Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4). Herein, we describe the structure-based design and optimization of alogliptin and related quinazolinone-based DPP-4 inhibitors. Following an oral dose, these noncovalent inhibitors provide sustained reduction of plasma DPP-4 activity and a lowering of blood glucose in animal models of diabetes. Alogliptin is currently undergoing phase 111 trials in patients with type 2 diabetes.